JournalArta
Friday, November 20, 2026 · JakartaS&P 7,175.83 ▼2.02%USD/IDR 18,260 ▲0.02%
JournalArta
Global Edition
beyond headlines
Advertisement

China Drug Deals Raise Supply Concerns, US Panel Warns

A US congressional commission says pharmaceutical licensing deals with Chinese biotechnology companies could increase American dependence on Chinese innovation. Its analysis of 57 deals comes as both governments consider restrictions affecting biotechnology trade and investment.

By Alistair Sterling
WIB2 min read
China Drug Deals Raise Supply Concerns, US Panel Warns
China Drug Deals Raise Supply Concerns, US Panel Warns

The National Security Commission on Emerging Biotechnology warned in a new analysis that China's drug supply chain ambitions could threaten US access to future treatments.

The commission examined 57 pharmaceutical deals from the beginning of 2023 through the month before its analysis. It found that Western drugmakers increasingly license treatments from Chinese companies, directing US capital toward China's pharmaceutical industry.

The warning comes as both countries consider restrictions affecting biotechnology. China proposed export restrictions on certain technologies, including cell and gene therapy platforms. Such therapies aim to treat disease using cells or genetic material.

Advertisement

Deals move earlier in development

In a typical licensing deal, a Chinese biotechnology company sells a multinational drugmaker the rights to develop or commercialize a treatment.

Western companies use the arrangements to shift some of the burden of drug discovery and verify early results. AstraZeneca, Bristol Myers Squibb and Pfizer are among the drugmakers drawn by China's life sciences investment and the promise of faster trials and approvals.

The commission found that deals increasingly rely on preclinical data, collected before a treatment reaches human trials. Upfront payments are also arriving earlier in research and development.

That timing gives Chinese partners capital and expertise in developing and commercializing treatments, the commission said. Royalties and stakes in joint ventures can flow back to China, funding research and infrastructure and attracting talent.

Advertisement

Commission Executive Director Caitlin Frazer said the deals risk eroding US biotechnology research and development. She added: “This trend should be alarming for policymakers.”

Washington weighs investment restrictions

The Trump administration proposed new screening requirements for certain deals with Chinese life sciences companies, as well as outright prohibitions for others.

The administration cited risks that investments could support biological weapons or surveillance technologies, or make US supply chains overly dependent on one country.

Under the proposal, cash-based deals involving royalties and payments tied to development milestones would remain permitted. Equity investments in Chinese firms would be prohibited, and certain joint ventures could also face restrictions, according to an analysis by Sidley.

Advertisement

Congress established the commission to examine the national security implications of emerging biotechnology. The panel called the proposed restrictions a prudent step, while urging policymakers to strengthen US innovation.

Brookings Institution senior fellow Marta Wosińska has noted that drug shortages can delay treatment for seizures, infections or severe pain.

In an earlier report to Congress, the commission described a hypothetical scenario in which Beijing withheld a breakthrough treatment from American patients during a conflict in Taiwan.

Advertisement
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Advertisement
Most Read
  1. 1Joachim Klement to Sell Stocks After S&P 500 Signal
  2. 2Stock Market Today: Dow Slides 1.34% and VIX Jumps 15% at Midday
  3. 3Kenneth Walker’s Groin Injury Puts Cardinals Game in Doubt
  4. 4McDonald’s Workers’ Discrimination Claims Can Go Ahead
  5. 5Pat Cummins Faces Captaincy Doubts From Mitchell Johnson
Advertisement
Don't Miss

Latest News

All stories →
  1. Markets · StocksSpaceX Shares Fall From Peak as Nvidia Raises StakeNov 20
  2. Markets · StocksNvidia and Intel Shares Fall After Earnings and OutlookNov 20
  3. Markets · StocksNvidia Shares Hit 52-Week Low After Huang’s ExitNov 20
  4. Markets · StocksMicrosoft Shares Rise 0.40% After Nadella Apologizes for OutageNov 20
  5. Advertisement
  6. Markets · StocksPermian Resources Earnings Rise as Oil Prices and Output ClimbNov 20
  7. Markets · CryptoBitcoin Beats XRP in Five-Year $100-a-Month ComparisonNov 20
  8. Technology · GamingGTA 6 Lets Players Build a Romance Alongside CrimeNov 20
  9. Lifestyle · EntertainmentWayne Rooney Says Wagatha Christie Case Affected ColeenNov 20